HRTX Heron Therapeutics Inc

Price (delayed)

$3.195

Market cap

$481.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$640.06M

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...

Highlights
Heron Therapeutics's EPS has surged by 56% YoY and by 26% QoQ
Heron Therapeutics's net income has increased by 46% YoY and by 27% from the previous quarter
The equity has dropped by 195% year-on-year
The debt is up by 14% year-on-year

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
150.65M
Market cap
$481.34M
Enterprise value
$640.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
Earnings
Revenue
$132.1M
EBIT
-$80.45M
EBITDA
-$77.58M
Free cash flow
-$44.71M
Per share
EPS
-$0.59
Free cash flow per share
-$0.3
Book value per share
-$0.22
Revenue per share
$0.87
TBVPS
$1.44
Balance sheet
Total assets
$217.89M
Total liabilities
$251.65M
Debt
$179.17M
Equity
-$33.77M
Working capital
$110.53M
Liquidity
Debt to equity
-5.31
Current ratio
2.47
Quick ratio
1.82
Net debt/EBITDA
-2.05
Margins
EBITDA margin
-58.7%
Gross margin
57.1%
Net margin
-61.3%
Operating margin
-62.3%
Efficiency
Return on assets
-37.2%
Return on equity
N/A
Return on invested capital
-28.1%
Return on capital employed
-56.5%
Return on sales
-60.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
-0.16%
1 week
-12.94%
1 month
-1.08%
1 year
131.52%
YTD
87.94%
QTD
-8.71%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$132.1M
Gross profit
$75.4M
Operating income
-$82.35M
Net income
-$80.95M
Gross margin
57.1%
Net margin
-61.3%
The net margin has soared by 54% year-on-year and by 30% since the previous quarter
HRTX's operating margin has surged by 51% year-on-year and by 28% since the previous quarter
Heron Therapeutics's net income has increased by 46% YoY and by 27% from the previous quarter
The operating income has increased by 43% year-on-year and by 26% since the previous quarter

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
Heron Therapeutics's EPS has surged by 56% YoY and by 26% QoQ
The equity has dropped by 195% year-on-year
HRTX's price to sales (P/S) is 93% more than its last 4 quarters average of 1.9 but 57% less than its 5-year quarterly average of 8.5
HRTX's revenue is up by 16% year-on-year and by 4% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has surged by 54% YoY and by 30% QoQ
The ROIC has grown by 48% YoY and by 29% from the previous quarter
HRTX's ROA is up by 39% YoY and by 26% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 13% lower than its total liabilities
The quick ratio has grown by 27% YoY and by 3.4% from the previous quarter
The current ratio has grown by 8% YoY and by 4.2% from the previous quarter
The equity has dropped by 195% year-on-year
The debt to equity has soared by 61% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.